{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:40:28Z","timestamp":1783021228694,"version":"3.54.6"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108252","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:24:07Z","timestamp":1764001447000},"page":"108252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy"],"prefix":"10.1016","volume":"163","author":[{"given":"Heidi","family":"Hempel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"La Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy J.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijid.2025.108252_bib0001","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal Infections Among Cancer Patients: A Population-Based Study in the United States","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0002","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41467-024-45307-x","article-title":"Causes of death among people living with metastatic cancer","volume":"15","author":"Mani","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2025.108252_bib0003","series-title":"The MD Anderson Manual of Medical Oncology, 4e","article-title":"Viral Infections in Patients with Cancer","author":"Khawaja","year":"2022"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0004","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1002\/cam4.5456","article-title":"Increased risk of death from pneumonia among cancer survivors: A propensity score-matched cohort analysis","volume":"12","author":"Tanaka","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s15010-022-01852-5","article-title":"Mortality in cancer patients with SARS-CoV-2 or seasonal influenza: an observational cohort study from a German-wide hospital network","volume":"51","author":"Kodde","year":"2023","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.ijid.2025.108252_bib0006","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0007","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1093\/cid\/ciab397","article-title":"Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019","volume":"73","author":"Haidar","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2025.108252_bib0008","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ijc.34798","article-title":"Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis","volume":"154","author":"Steinberg","year":"2024","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.ijid.2025.108252_bib0009","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.21.01074","article-title":"Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)","volume":"39","author":"Sharafeldin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10238-023-01004-5","article-title":"Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis","volume":"23","author":"Hardy","year":"2023","journal-title":"Clin Exp Med"},{"issue":"10241","key":"10.1016\/j.ijid.2025.108252_bib0011","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol"},{"issue":"10241","key":"10.1016\/j.ijid.2025.108252_bib0013","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijid.2025.108252_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00262-021-02990-9","article-title":"Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis","volume":"71","author":"Lazarus","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijid.2025.108252_bib0015","unstructured":"U.S. Food and Drug Administration. \"FDA approves first treatment for COVID-19.\" https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 (accessed July 28, 2025)."},{"key":"10.1016\/j.ijid.2025.108252_bib0016","unstructured":"U.S. Food and Drug Administration. \"Frequently asked questions on the Emergency Use Authorization for Pemgarda (pemivibart) for pre\u2011exposure prophylaxis (PrEP) of COVID\u201119.\" https:\/\/www.fda.gov\/media\/177066\/download (accessed July 28, 2025)."},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s43856-024-00549-0","article-title":"Identification of risk factors of Long COVID and predictive modeling in the RECOVER EHR cohorts","volume":"4","author":"Zang","year":"2024","journal-title":"Communications Medicine"},{"key":"10.1016\/j.ijid.2025.108252_bib0018","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81182","article-title":"Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period","volume":"12","author":"Dagher","year":"2023","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.ijid.2025.108252_bib0019","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis","volume":"5","author":"Raglow","year":"2024","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.ijid.2025.108252_bib0020","article-title":"Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium","volume":"19","author":"Choueiri","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.ijid.2025.108252_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ijid.2025.108252_bib0022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ijc.34209","article-title":"Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients","volume":"152","author":"Zaleska","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijid.2025.108252_bib0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijid.2025.108252_bib0024","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2022.05.029","article-title":"Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis","volume":"172","author":"Mai","year":"2022","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.ijid.2025.108252_bib0025","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chroni c lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ijid.2025.108252_bib0026","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bjh.18549","article-title":"Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies","volume":"200","author":"Ikeda","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ijid.2025.108252_bib0027","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.ijid.2025.108252_bib0028","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17402","article-title":"Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults","volume":"8","author":"Link-Gelles","year":"2025","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.ijid.2025.108252_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","article-title":"Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population","volume":"29","author":"Lau","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/j.ijid.2025.108252_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1629473","article-title":"Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters","volume":"16","author":"Xue","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ijid.2025.108252_bib0032","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2666-5247(23)00258-6","article-title":"The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays","volume":"5","author":"Hempel","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2025.108252_bib0033","doi-asserted-by":"crossref","unstructured":"VP Rocha, et al., \u201cAn overview of the conventional and novel methods employed for SARS-CoV-2 neutralizing antibody measurement,\u201d Viruses, vol. 15, no. 7, doi:10.3390\/v15071504.","DOI":"10.3390\/v15071504"},{"key":"10.1016\/j.ijid.2025.108252_bib0034","article-title":"T and B cell responses in different immunization scenarios for COVID-19: a narrative review","author":"Mortari","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.ijid.2025.108252_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","article-title":"Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children","volume":"40","author":"Loske","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ijid.2025.108252_bib0036","article-title":"The underlying mechanism behind the different outcomes of COVID-19 in children and adults","author":"Shang","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/j.ijid.2025.108252_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ijid.2025.108252_bib0038","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"Lancet Microbe"},{"issue":"6","key":"10.1016\/j.ijid.2025.108252_bib0039","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2021006627","article-title":"Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study","volume":"6","author":"Haydu","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ijid.2025.108252_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126723","article-title":"Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination","volume":"48","author":"Raineri","year":"2025","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ijid.2025.108252_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007387","article-title":"Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment","volume":"11","author":"Donhauser","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0042","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13027-023-00526-7","article-title":"COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study","volume":"18","author":"Qian","year":"2023","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-023-00794-9","article-title":"A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation","volume":"9","author":"Binayke","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"11","key":"10.1016\/j.ijid.2025.108252_bib0044","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41587-022-01347-6","article-title":"Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR","volume":"40","author":"Schwarz","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0045","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1038\/s41467-021-24377-1","article-title":"SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2025.108252_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127175","article-title":"Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination","volume":"56","author":"Paul","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0047","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1038\/s41467-025-60726-0","article-title":"Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial","volume":"16","author":"Jeyanathan","year":"2025","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.ijid.2025.108252_bib0048","doi-asserted-by":"crossref","first-page":"ofaf021","DOI":"10.1093\/ofid\/ofaf021","article-title":"Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions","volume":"12","author":"Crawford","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_4","key":"10.1016\/j.ijid.2025.108252_bib0049","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1093\/cid\/ciae511","article-title":"Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.ijid.2025.108252_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cmi.2024.10.026","article-title":"Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: a population-based, retrospective cohort study","volume":"31","author":"Jorda","year":"2025","journal-title":"Clinical Microbiology and Infection"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:47:12Z","timestamp":1783018032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["S1201971225004746"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108252","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108252"}}